Single-cell dissection of crizotinib persister cells in ALK⁺ ALCL PDX in vivo. (A) Uniform manifold approximation and projection (UMAP) global cluster annotation based on single-cell RNA sequencing (Seq) expression (IL-69 and IL-79 PDX models treated with crizotinib or vehicle). (B) PDX-specific (IL-69 left panel and IL-79 right panel) UMAP cluster annotation based on single-cell RNA-seq expression of PDXs treated with crizotinib or vehicle. (C) Bar graph depicting the percent contribution of IL-69 cells receiving crizotinib (orange bars) or control (blue bars) to each cluster (CL0-CL6). (D) Bar graph depicting the percent contribution of IL-79 cells receiving crizotinib (orange bars) or control (blue bars) to each cluster (CL0-CL6). (E) Bar graph revealing the normalized enrichment score from the pathway hallmark analysis based on CL3 markers in IL-69 and IL-79 PDXs treated with crizotinib or with control. (F) Gene set enrichment analyses (GSEAs) of the “GOBP: T-cell Apoptotic Process – upper panel” and the “GOBP: Leukocyte Apoptotic Process – lower panel” based on CL3 markers in IL-69 and IL-79 PDXs treated with crizotinib or with control. (G) GSEAs of the “Hallmark_APOPTOSIS” between the crizotinib treated cells in CL3 vs the crizotinib treated cells in CL0 (i), CL1 (ii), CL2 (iii), CL4 (iv), and CL5 (v). CL3 was enriched of cells coming from crizotinib-treated PDXs (IL-69 and IL-79).